Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis.

In contrast, the aggregated OS-12 of celecoxib in combination with TKIs or radiotherapy showed no significant improvement (P=0.1, P=0.13), with a highly significant difference between radiotherapy and chemotherapy or TKIs (67% vs 39%, P=0.0359 or 67% vs 35%, P=0.0321) and with no significant difference between chemotherapy and TKIs in terms of one-year survival (39% vs 35%, P=0.5751).

also in 132,142 other papers